Derma Sciences

Derma Sciences is a company focused on advanced wound care and tissue regeneration, providing innovative solutions to healthcare providers for the effective management of complex wounds. Derma Sciences specializes in advanced wound care, offering products designed to support healing in various wound types. The company is headquartered in Princeton, US. Led by CEO Muhammad Haseeb, Derma Sciences has secured a total funding amount of USD 29.

08 mn through its latest funding round, PIPE, which included investors Deerfield Management, Jennison Associates, and RA Capital. The company has successfully completed 3 deals. Derma Sciences offers a wide range of products for advanced wound care, including engineered collagen products and acellular dermal matrices. Their core offerings such as the Integra® Dermal Regeneration Template and Integra® Bilayer Wound Matrix help facilitate healing in complex wounds.

The PriMatrix® Dermal Repair Scaffold is an acellular dermal matrix made from fetal bovine dermis, while their Urinary Bladder Matrix serves as a basis for products like Cytal® Wound Matrix and MicroMatrix® Flex. These products are marketed primarily to healthcare professionals in North America, Europe, and select Asian markets. In the most recent year, Derma Sciences reported a revenue of USD 84. 47 mn, with an EBITDA of USD -18.

05 mn. Derma Sciences aims to enhance its product portfolio with upcoming advancements in wound care solutions. The company plans to expand its operations into new geographic markets, focusing on regions in Asia and Europe by 2025. The recent funding of USD 29.

08 mn will support these initiatives, allowing for increased research and development efforts as well as marketing strategies to penetrate these new markets.